Table 1. Characteristics of MRONJ Patients managed with PENT-E.

Age(y) /Sex /Stage	No. of doses prior to ONJ	Clinical presentation prior to PENT-E	Radiographic findings prior to PENT-E	Duration on PENT-E till last follow-up	Clinical presentation at last follow-up	Radiographic findings at last follow-up
1. 63/M /3	40, Z + S	Pain, purulent discharge, mandibular bone exposure (55 mm)	Radiolucent defect reaching the basal bone	48 months	No pain, discharge or bone exposure	Radiolucent bony defect filling
2. 66 /M /3	35Z + 11 A	Pain, purulent discharge, bilateral mandibular bone exposure	Radiolucent defects reaching the basal bone	13 months	No pain, discharge, bone exposure unchanged	Radiolucent bony defect filling
3. 54 /M /3	40, Z	Pain, purulent discharge, mandibular bone exposure	Radiolucent defect reaching the basal bone	22 months	No pain, discharge or bone exposure	Radiolucent bony defect filling
4. 62/F /2	7Z + 2D	Pain, discharge and bone exposure	No radiographic findings	3 months	No pain or discharge, bone exposure reduced in size	NA
5. 57/F /2	8, D	Pain and bone exposure: right maxilla (8 mm), left maxilla (6 mm) and mandible	No radiographic findings	5 months	No pain or bone exposure on the right maxilla, bone exposure on the left maxilla reduced to 2 mm. The mandibular bone exposure unchanged	NA
6. 68 /F /2	100, Z	Pain, bilateral mandibular bone exposure	No radiographic findings	3 months	No pain, bone exposure reduced in size	NA
7. 53 /F /0	63, Z	Pain, swelling, no exposed bone	Radiolucent defect	24 months	No pain or swelling	Radiolucent bony defect filling

Z – Zolendronic acid, S – Sunitinib, A – Alendronic acid, D - Denosumab, NA - Not applicable